Research and Development in Wound Care: Building the Next Big Thing

The field of wound care is shifting from a passive, reactive field to one that is active and driven by technology. Gone are the days when a wound dressing simply provided a protective barrier. Today’s advanced wound care solutions are designed to actively promote tissue regeneration, manage exudate, and provide real-time data to clinicians.

This technological evolution is powered by a robust and often complex research and development lifecycle. For practitioners like you, understanding this journey—from the initial spark of an idea to its arrival in the clinic—helps you make informed decisions about product adoption. This guide will demystify research and development in wound care, from rigorous testing to the intricate web of regulatory and policy pathways, and provide insights that can help you confidently navigate a rapidly changing wound care product market and deliver even better patient care.

Research & Development in Wound Care: From Bench to Bedside

The journey of a new wound care product from a lab concept to clinical use is a complex, multi-stage process. This pipeline ensures that only products that are safe, effective, and backed by robust evidence make it into your practitioner arsenal.

Idea Generation

Ideas for new wound care solutions often stem from an unmet clinical need. This can come directly from the front lines of care, with clinicians identifying challenges in managing chronic wounds, or from fundamental advances in biomaterial science and regenerative medicine from academic research.

Innovations may focus on improving existing products (think: adding antimicrobial properties to a dressing) or creating entirely new solutions, such as bioengineered skin substitutes. The process is a collaborative loop, with feedback from practitioners often driving the next generation of research.

Preclinical Testing

Before a new therapy can be tested on humans, it must undergo rigorous preclinical testing to demonstrate initial safety and efficacy. This phase includes both in vitro (in a lab setting) and in vivo (in living organisms) studies.

In vitro testing may involve using cell cultures to evaluate a material’s biocompatibility and its effect on cellular growth and viability. In vivo studies often use animal models, such as porcine or diabetic mouse models, to simulate wound healing in a controlled environment. These studies help researchers understand how a product interacts with living tissue, its ability to reduce infection, and its overall impact on the healing process.

Clinical Trials and Evidence

Clinical trials are the gold standard for proving a product’s effectiveness and safety in humans. They are typically conducted in phases, like:

• Phase I trials are small-scale studies (typically involving 20–80 people). Researchers identify the best way to administer the product, find a safe dosage range, and monitor closely for any severe side effects. The primary goal is to assess safety, not efficacy.
• Phase II trials are larger (involving 100–300 people) and designed to assess efficacy, exploring whether the product works as intended for a specific indication, and further test its safety.
• Phase III trials are the largest (often expanding to 1,000–3,000 people) and compare the new product against the current standard of care to confirm its effectiveness—or superiority in some cases—and to detect any important side effects.
• Phase IV trials occur after a product has received regulatory approval and is available to the public. These extended studies are designed to collect more information on a product’s optimal use and long-term safety in a real-world setting.

Though many clinical trials follow a four-phase structure, some don’t go through every phase. Ultimately, trials vary depending on purpose, design, outcome, and other factors.  

As a practitioner, your most critical takeaway is the type of evidence that matters most: data from peer-reviewed studies published in high-impact journals. This evidence base is what gives a product its credibility and informs your decision making, ensuring you are providing care that’s both safe and effective.

Navigating the FDA’s Regulatory Requirements

The path to market for a new wound care product is heavily regulated by government agencies like the Food and Drug Administration (FDA), which determines not only a product’s safety but also its effectiveness for public health.

The FDA classifies medical devices into three risk-based classes:

• Class I (low risk)
• Class II (moderate risk)
• Class III (high risk)

This classification dictates the regulatory pathway a product must take to market, directly determining the type of evidence required. For wound care products, the most common pathways to market include the 510(k), De Novo, and premarket approval processes.

Premarket Notification 510(k)

Often referred to as simply 510(k), this is the most common pathway for medical devices. It’s used when a device is “substantially equivalent” to a device already on the market (a “predicate device”), which generally means it has the same intended use and technological characteristics as the predicate.

Notably, the manufacturer must demonstrate that the new device is as safe and effective as the predicate. This often requires bench testing and biocompatibility studies, but clinical data is generally not required unless there are significant technological differences. In wound care, this process is typically used for less complex wound dressings and topical treatments.

De Novo Classification Request

The De Novo classification request is for novel, low- to moderate-risk devices that do not have a legally marketed predicate device. This pathway creates a new device classification for a product and serves as a predicate for future 510(k) submissions.

Because the device is new to the market, the FDA requires more robust data to demonstrate safety and effectiveness, such as:

• Clinical data (if applicable).
• Non-clinical data including bench performance testing.
• Information on aspects such as shelf life, biocompatibility, and software.
• Probable benefits of the device compared to any anticipated risks.

Premarket Approval (PMA) Applications

The most rigorous and resource-intensive pathway, PMA applications are required for Class III devices that present a high risk, such as those that are life sustaining, life supporting, or intended for a use that is of substantial importance in preventing impairment of human health.

PMAs require extensive clinical trial data to provide reasonable assurance of safety and effectiveness, including:

• Manufacturing information, such as the methods, facilities, and controls used to manufacture the device.
• Non-clinical laboratory studies on microbiology, toxicology, immunology, biocompatibility, and other areas.
• Clinical investigations details, such as study protocols, safety and effectiveness data, adverse reactions and complications, device failures and replacements, patient information and complaints, and more.
• Quality system information with a complete description of the design controls implemented to comply with the quality system regulation.
• Proposed labeling for the device that complies with the requirements in the Code of Federal Regulations, specifically 21 CFR Part 801 or 21 CFR Part 809.

Given the rigor required of PMA application, the FDA is even more stringent about not only the requirements, but also its review:

“If a PMA application lacks elements listed in the administrative checklist, FDA will refuse to file a PMA application and will not proceed with the in-depth review of scientific and clinical data. [Further…] PMA applications that are incomplete, inaccurate, inconsistent, omit critical information, and poorly organized have resulted in delays in approval or denial of those applications.”

CMS Crackdown on Skin Substitutes

The Centers for Medicare & Medicaid Services (CMS) has recently enacted a profound shift in reimbursement policy for skin substitutes.

Spurred by an unprecedented increase in spending—rising from $256 million in 2019 to over $10 billion in 2024, according to Medicare Part B claims data—CMS is cracking down on what it views as excessive spending and improper billing. This change has prompted a shift away from the traditional model of reimbursement.

Proposed Changes to Reimbursement

CMS is proposing to reclassify most skin substitutes, which are currently reimbursed on an average sales price (ASP) basis as “biologicals.” Instead, they would be categorized as “incident-to supplies,” a change that would reduce spending on these products by an estimated 90%.

Emphasis on Evidence and Documentation

New Local Coverage Determinations (LCDs) are being introduced starting January 1, 2026, to limit the types of products covered and the number of applications allowed. CMS is emphasizing the need for robust clinical documentation and justification for the use of skin substitutes, with insufficient documentation potentially leading to increased audits and recoupment demands.

The Impact on the Market

This regulatory shift has forced manufacturers to pivot their strategies in research and development in wound care. The old model, which often prioritized aggressive marketing and sales teams to drive adoption, is no longer financially viable. The new landscape demands a focus on robust clinical data to prove a product’s value.

Manufacturers are now investing heavily in high-quality, peer-reviewed clinical studies to demonstrate that their products are not just effective, but also cost-effective for the provider and for the system.

The Future of Wound Care

The new regulatory environment is shaping the next generation of wound care products, forcing manufacturers to create solutions with demonstrably superior patient outcomes and clear value propositions. Beyond this policy-driven shift, several technological advancements are poised to revolutionize how practitioners manage and treat wounds.

Biomaterials and Regenerative Medicine

Next-gen wound care products are moving beyond traditional dressings to actively support tissue regeneration. Advances in bioengineered scaffolds, for example, are creating new acellular matrices (like AlloSkin and Integra) that provide the structural framework for new tissue to grow.

Hydrogels, another area of rapid innovation, are now being engineered as smart materials that can be loaded with growth factors, stem cells, or other regenerative agents to promote accelerated healing. This is a significant shift from products that simply protect a wound to those that are bioactive and therapeutic.

Data-Driven Diagnostics

The rise of artificial intelligence (AI) and machine learning is making wound assessment more objective and predictive than ever before. New technologies are emerging that use computer vision to analyze wound images captured by a smartphone or camera.

AI algorithms can objectively measure wound size, identify tissue types (e.g., granulation, necrotic), and even predict healing trajectories with high accuracy. These data-driven insights help clinicians track progress more effectively, personalize treatment plans, and intervene early if a wound is at risk of stalling. This helps move wound care from a subjective visual assessment to a more precise, quantitative science.

Telemedicine and Remote Monitoring

Telehealth is increasing accessibility to wound care specialists, especially for patients in rural or home-health settings. Synchronous (video-based) and asynchronous (store-and-forward) telemedicine platforms allow practitioners to evaluate wounds, provide guidance to onsite caregivers, and manage treatment plans without the need for an in-person visit.

This is being paired with remote monitoring technologies, such as sensor-embedded smart dressings, that can continuously track key wound parameters like temperature, pH levels, and glucose. This real-time data allows for immediate alerts if a complication arises, reducing the need for routine in-office follow-ups and enabling proactive, continuous care.

Research & Development in Wound Care: A New Era of Evidence-Based Products

The future of wound care is at the exciting intersection of policy, innovation, and patient outcomes. The CMS crackdown on skin substitute reimbursement is driving manufacturers to innovate with products that are not just effective but also cost-efficient, forcing a new era of evidence-based care.

As technology continues to advance in the areas of biomaterials, AI, and telehealth, practitioners are gaining powerful new tools to heal complex wounds. This shift toward a more rigorous, data-driven approach promises a more effective and sustainable landscape for both practitioners and patients.